Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528684 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
A Phase 1 study of Malignant Glioma, sponsored by Oncolytics Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT00528684: Completed Phase 1 study of Malignant Glioma, sponsored by Oncolytics Biotech.
NCT00528684 is a Phase 1 study of Malignant Glioma that has completed, run by Oncolytics Biotech. The registered enrollment target is 18 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00528684, a Phase 1 study of Malignant Glioma, has completed, sponsored by Oncolytics Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Oncolytic viruses such as reovirus (REOLYSIN®) can specifically kill tumor cells while leaving healthy cells unharmed. PURPOSE: This phase I/II study investigates the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and anti-tumor effect of intralesional administration of REOLYSIN® therapeutic reovirus in patients with malignant glioma with evaluable disease which is progressive/recurrent despite surgery and/or radiotherapy with or without chemotherapy. (The phase I portion of the study is currently enrolling patients.)
Conditions Studied
Interventions
- BIOLOGICAL REOLYSIN®
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Cedars-Sinai Medical Center - Los Angeles
Ohio
- The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
What the finished NCT00528684 record still lists
NCT00528684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which REOLYSIN® is the first listed.
NCT00528684 reports a single indexed study location in Alabama, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT00528684 about?
NCT00528684 is a clinical study titled "Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas". RATIONALE: Oncolytic viruses such as reovirus (REOLYSIN®) can specifically kill tumor cells while leaving healthy cells unharmed. PURPOSE: This phase I/II study investigates the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and anti-tumor effect of intralesional administration of REOLY...
What is the current status of trial NCT00528684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-07. Estimated completion is 2010-06.
What conditions does trial NCT00528684 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT00528684?
The interventions under investigation include: REOLYSIN® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00528684?
This trial is sponsored by Oncolytics Biotech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00528684 being conducted?
This trial has 3 study locations across Alabama, California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00528684's enrollment target sits among peer trials
18 36th of 40 higher than 3 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia